Compare · DFTX vs PRDS
DFTX vs PRDS
Side-by-side comparison of Definium Therapeutics Inc. (DFTX) and Pardes Biosciences Inc. (PRDS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both DFTX and PRDS operate in Medicinal Chemicals and Botanical Products (Health Care), so they compete in similar markets.
- DFTX is the larger of the two at $5.21B, about 7.9x PRDS ($657.5M).
- DFTX has hit the wire 16 times in the past 4 weeks while PRDS has been quiet.
- DFTX has more recent analyst coverage (7 ratings vs 3 for PRDS).
- Company
- Definium Therapeutics Inc.
- Pardes Biosciences Inc.
- Price
- $38.81+0.27%
- $2.19+1.39%
- Market cap
- $5.21B
- $657.5M
- 1M return
- -15.33%
- -
- 1Y return
- +330.27%
- -
- Industry
- Medicinal Chemicals and Botanical Products
- Medicinal Chemicals and Botanical Products
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2021
- News (4w)
- 16
- 0
- Recent ratings
- 7
- 3
PRDS
Pardes Biosciences Inc.
Pardes Biosciences, Inc., a clinical stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics to improve the lives of patients suffering from life-threatening disease. Its lead candidate is the PBI-0451 that is in clinical development stage to treat and prevent severe acute respiratory syndrome coronavirus 2 infections and associated diseases. The company was incorporated in 2020 and is headquartered in Carlsbad, California.
Latest DFTX
- Director Vallone Carol A exercised 1,086 shares at a strike of $35.52, increasing direct ownership by 5% to 22,296 units (SEC Form 4)
- Director Krebs Andreas exercised 1,629 shares at a strike of $35.52, increasing direct ownership by 8% to 21,402 units (SEC Form 4)
- Chief Executive Officer Barrow Robert was granted 750,000 shares, increasing direct ownership by 50% to 2,244,640 units (SEC Form 4)
- Chief Legal Officer Sullivan Mark was granted 125,000 shares, increasing direct ownership by 33% to 508,279 units (SEC Form 4)
- Chief Financial Officer Roberts Brandi was granted 125,000 shares, increasing direct ownership by 46% to 397,905 units (SEC Form 4)
- Chief Commercial Officer Wiley Matthew T. was granted 125,000 shares, increasing direct ownership by 53% to 362,133 units (SEC Form 4)
- Chief Medical Officer Karlin Daniel was granted 200,000 shares, increasing direct ownership by 33% to 803,699 units (SEC Form 4)
- Definium Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Definium Therapeutics Announces Positive Topline Results from Phase 3 Panorama Study of DT120 ODT in Generalized Anxiety Disorder
- Definium Therapeutics Announces New Employee Inducement Grants
Latest PRDS
- SEC Form 15-12G filed by Pardes Biosciences Inc.
- SEC Form EFFECT filed by Pardes Biosciences Inc.
- SEC Form EFFECT filed by Pardes Biosciences Inc.
- SEC Form 4: Tananbaum James B. returned 16,813,146 shares to the company and acquired 1,000 shares
- SEC Form SC 13D/A filed by Pardes Biosciences Inc. (Amendment)
- SEC Form 4: Wiggans Thomas G closing all direct ownership in the company
- SEC Form 4: Varney Michael David closing all direct ownership in the company
- SEC Form 4 filed by Smaldone Alsup Laurie
- SEC Form 4 filed by Pottage John C Jr
- SEC Form 4: Lopatin Uri A closing all direct ownership in the company